FDA approved zilganersen as the first disease-modifying therapy for Alexander disease, an ultra-rare, progressive ...
Eli Lilly & Company and Merida Biosciences announced a definitive agreement for Eli Lilly to acquire Merida, to advance ...
In a conversation with Pharmaceutical Executive, Nate Hill, Co-Founder & CEO of Strive Pharmacy, discussed the regulatory ...
Ionis wins FDA approval for Zanvastro, the first disease-modifying treatment for Alexander disease, Pharmaceutical ...
Ultragenyx is reviewing program disposition and implementing significant expense reductions as brokerages cut price targets ...
Ionis wins FDA approval for Zanvastro, the first disease-modifying treatment for Alexander disease, Pharmaceutical Executive’s weekly biotech roundup gathers analyst reaction to the week's biggest ...
Simcere Zaiming has licensed its first-in-class tri-specific CD79a/CD19/CD3 T-cell engager Sim0660 to Roche for up to $1.53 ...
Eli Lilly agrees to acquire Merida Biosciences for up to $2.875 billion, BioNTech halts a Phase II trial of its cancer ...
The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA ...
Recently, Pharmaceutical Executive spoke with Christian Thienel, director at Back Bay Life Sciences, about the ongoing issues ...
Nate Hill, co-founder & CEO, Strive, notes the key milestone to watch for during the remaining step in FDA's formal Category ...
When treating IBD, what are the restraints with JAK inhibitors? Christian Thienel: JAK inhibitors have been around for quite a while, and they are understood to be highly effective. The JAK-STAT ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results